MPG

DNA-3-methyladenine glycosylase · P29372 · MPG on Sugi Atlas →

626 patent compounds predicted against MPG, 506 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Morin (SCHEMBL19984)	1.00	2/20
Morin (SCHEMBL294933)	1.00	2/20
Morin (SCHEMBL7116848)	1.00	2/20
Morin (SCHEMBL10335390)	1.00	2/20
Morin (SCHEMBL15106661)	1.00	2/20
Morin (SCHEMBL29400568)	1.00	2/20
Morin (SCHEMBL29435805)	1.00	2/20
Morin (SCHEMBL29929115)	1.00	2/20
Morin (SCHEMBL21874430)	0.97	2/20
Morin (SCHEMBL8165525)	0.89	2/20
Morin (SCHEMBL3723616)	0.83	2/20
Morin (SCHEMBL11734524)	0.80	2/20
SCHEMBL10716775	0.79	2/20
SCHEMBL14008303	0.78	2/20
Datiscetin (SCHEMBL43916)	0.78	2/20
Datiscetin (SCHEMBL29737517)	0.78	2/20
Datiscetin (SCHEMBL30822630)	0.78	2/20
Morin (SCHEMBL21874426)	0.78	2/20
SCHEMBL14004949	0.76	2/20
Morin (SCHEMBL21874424)	0.76	2/20

Clinical trials — most relevant to MPG by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)	PHASE2	NOT_YET_RECRUITING
Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)	PHASE1/PHASE2	UNKNOWN
Thiopurine EnhAnced Maintenance Therapy	PHASE1/PHASE2	COMPLETED
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
NIVOLUMAB Plus IPILIMUMAB and TEMOZOLOMIDE in Microsatellite Stable, MGMT Silenced Metastatic Colorectal Cancer	PHASE2	COMPLETED
Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor	PHASE1/PHASE2	NOT_YET_RECRUITING
Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy	PHASE1/PHASE2	COMPLETED
Phase II ABT-888 With Cyclophosphamide	PHASE2	COMPLETED
Olaparib in People With Malignant Mesothelioma	PHASE2	COMPLETED
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study to Compare CAPTEM vs FOLFIRI as Second Line Treatment in Advanced, Colorectal Cancer Patients	PHASE2	COMPLETED
Niraparib and Temozolomide in Patients Glioblastoma	PHASE1/PHASE2	NOT_YET_RECRUITING
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM	PHASE1	ACTIVE_NOT_RECRUITING
Phase I Trial of 4'-Thio-2'-Deoxycytidine (TdCyd) in Patients With Advanced Solid Tumors	PHASE1	COMPLETED
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors	PHASE1	RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
FTT PET/CT in Pancreatic Neuroendocrine Tumors	PHASE1	RECRUITING
Preoperative CRT With Temozolomide Plus Capecitabine in Rectal Cancer	PHASE1	COMPLETED
BGB-58067 in Newly Diagnosed Glioblastoma Patients With MTAP-Deleted Tumors	EARLY_PHASE1	RECRUITING
Application of Genetic Polymorphisms of DNA Repair in The Prediction of Prostate Cancer Susceptibility and Its Clinical Outcome	nan	UNKNOWN
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
Prognosis of METTL-14 in Endometrial Carcinoma	nan	NOT_YET_RECRUITING
Impact of O6-methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and MGMT Expression on Dacarbazine Treated Sarcoma Patients (MGMT)	nan	UNKNOWN
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
The Influence of Thiopurine Methyltransferase Activity on Toxicity After High-dose Methotrexate in Childhood Acute Lymphoblastic Leukemia	nan	COMPLETED
Studying Tissue Samples From Patients With Stage II Colon Cancer Treated on Clinical Trial CLB-9581	nan	COMPLETED
DNA Repair Genes and Outcomes in Patients With Stage III NSCLC	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a MPG binder may also engage these)

Protein	Name	Similarity
Q04841	—	0.983	Q04841 →
P23571	—	0.969	P23571 →
Q8K4Q6	—	0.956	Q8K4Q6 →
Q96FI4	—	0.951	Q96FI4 →
Q8IW40	—	0.947	Q8IW40 →
Q02833	—	0.944	Q02833 →
Q32PI0	—	0.943	Q32PI0 →
Q8N9H8	—	0.943	Q8N9H8 →
PML	Protein PML	0.942	landscape →
Q96JH8	—	0.941	Q96JH8 →
A6QNS9	—	0.941	A6QNS9 →
Q9ESG9	—	0.940	Q9ESG9 →
A1L3C1	—	0.940	A1L3C1 →
Q9DD19	—	0.940	Q9DD19 →
Q96FB5	—	0.940	Q96FB5 →
O43189	—	0.940	O43189 →
D3ZVU9	—	0.939	D3ZVU9 →
Q8IZ69	—	0.939	Q8IZ69 →
Q6GQT6	—	0.939	Q6GQT6 →
Q3UGX3	—	0.939	Q3UGX3 →
A2RRU4	—	0.938	A2RRU4 →
Q6ZN54	—	0.938	Q6ZN54 →
Q96NA8	—	0.937	Q96NA8 →
Q8BQB4	—	0.937	Q8BQB4 →
Q7Z6G3	—	0.937	Q7Z6G3 →
PKMYT1	Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase	0.937	landscape →
Q32L49	—	0.937	Q32L49 →
P97260	—	0.936	P97260 →
Q66T02	—	0.936	Q66T02 →
A6QM06	—	0.936	A6QM06 →